Polycystic ovary syndrome has been officially renamed polyendocrine metabolic ovarian syndrome, a change driven by over 50 organisations to enhance awareness and improve healthcare outcomes for millions of women worldwide.
A major health condition affecting more than 170 million women worldwide has officially been renamed following a global effort led by Monash University, in Melbourne, Australia.
Polycystic ovary syndrome (PCOS) will now be known as polyendocrine metabolic ovarian syndrome (PMOS), reflecting growing evidence that the condition extends far beyond ovarian cysts and it affects multiple systems in the body.
The change, published in The Lancet, follows 14 years of international collaboration involving patients, researchers, and 56 medical and advocacy organisations.
The transition to the new name will take place over three years, with PMOS expected to be formally adopted in the 2028 international guideline update.
